Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Lixte Biotechnology Holdings, Inc. - Common Stock (NQ:LIXT)

2.510 +0.070 (+2.87%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 9, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	50,767
Open	2.390
Bid (Size)	2.510 (100)
Ask (Size)	2.650 (100)
Prev. Close	2.440
Today's Range	2.360 - 2.670
52wk Range	0.6400 - 6.260
Shares Outstanding	5,704,200
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Building a New Cancer Care Ecosystem: Liora’s Proton Therapy and LIXTE’s Drug Pipeline in Synergy

Today 12:05 EDT

Via Investor Brand Network

TinyGemsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Adds Innovative LiGHT Therapy to Pipeline

March 06, 2026

Via Investor Brand Network

Performance

YTD	-34.6%	-34.6%
1 Month	-14.9%	-14.9%
3 Month	-42.2%	-42.2%
6 Month	-42.0%	-42.0%
1 Year	+114.5%	+114.5%

More News

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances Lead Compound in Tumor Immunogenicity Research

March 06, 2026

Via Investor Brand Network

Liora, a subsidiary of LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), Introduces New CEO, Brings Experience to Treating Tumors with Proton Therapy

March 02, 2026

Via Investor Brand Network

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Expands into Proton Therapy Through Liora Technologies, Advancing the LiGHT System for Next-Generation Cancer Care

February 23, 2026

Via Investor Brand Network

When Cancer Care Hits a Hardware Wall, One Microcap Is Building Around It

February 18, 2026

Via Investor Brand Network

BioMedNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Appoints Sidney Braun as CEO of Liora Technologies Europe Subsidiary

February 18, 2026

Via Investor Brand Network

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Focused on Dual Narratives of Scientific Progress, Social Engagement

February 13, 2026

Via Investor Brand Network

BioMedNewsBreaks — LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Bringing First-in-Class Approach to Chemo and Immunotherapy

February 11, 2026

Via Investor Brand Network

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Aligns Liora and the LiGHT System With LB-100 to Push the Frontier of Cancer Treatment

February 09, 2026

Via Investor Brand Network

InvestorNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Positions LB-100 to Expand Effectiveness of Standard Cancer Treatment

February 06, 2026

Via Investor Brand Network

MissionIRNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Positions LB-100 to Expand Effectiveness of Standard Cancer Treatment

February 06, 2026

Via Investor Brand Network

Improving the Odds: How LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Is Working to Make Cancer Therapies More Effective

February 04, 2026

Via Investor Brand Network

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances a Novel Approach to Enhancing Cancer Therapy

January 22, 2026

Via Investor Brand Network

BioMedNewsBreaks — LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Sponsors Good Health Mind, Body and Soul Summit at Morehouse College

January 21, 2026

Via Investor Brand Network

InvestorNewsBreaks – Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) to Participate In DealFlow Discovery Conference

January 20, 2026

Via Investor Brand Network

TinyGemsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Engages IBN to Support Corporate Communications Strategy

January 13, 2026

Via Investor Brand Network

BioMedNewsBreaks – Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) Expands Ovarian Cancer Trial With MD Anderson and GSK

January 08, 2026

Via Investor Brand Network

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Is ‘One to Watch’

January 07, 2026

Via Investor Brand Network

BioMedNewsBreaks — Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) Announces $4.3 Million Registered Direct Offering Priced at Market

January 07, 2026

Via Investor Brand Network

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.’s $4.3 Million Registered Direct Offering

December 22, 2025

From Spartan Capital Securities, LLC

Via GlobeNewswire

LIXTE's Strategy Comes Into Focus: Building an Oncology Platform Around Complementary Modalities

December 08, 2025

Via ACCESS Newswire

LIXTE Levels Up From PP2A Innovation to Multi-Modal Oncology

December 03, 2025

Via ACCESS Newswire

LIXTE Steps Into a Key Role in the Rise of Treatment Amplifiers

December 03, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

October 15, 2025

Via Benzinga

Frequently Asked Questions

Is Lixte Biotechnology Holdings, Inc. - Common Stock publicly traded?

Yes, Lixte Biotechnology Holdings, Inc. - Common Stock is publicly traded.

What exchange does Lixte Biotechnology Holdings, Inc. - Common Stock trade on?

Lixte Biotechnology Holdings, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Lixte Biotechnology Holdings, Inc. - Common Stock?

The ticker symbol for Lixte Biotechnology Holdings, Inc. - Common Stock is LIXT on the Nasdaq Stock Market

What is the current price of Lixte Biotechnology Holdings, Inc. - Common Stock?

The current price of Lixte Biotechnology Holdings, Inc. - Common Stock is 2.510

When was Lixte Biotechnology Holdings, Inc. - Common Stock last traded?

The last trade of Lixte Biotechnology Holdings, Inc. - Common Stock was at 03/09/26 04:00 PM ET

What is the market capitalization of Lixte Biotechnology Holdings, Inc. - Common Stock?

The market capitalization of Lixte Biotechnology Holdings, Inc. - Common Stock is 14.32M

How many shares of Lixte Biotechnology Holdings, Inc. - Common Stock are outstanding?

Lixte Biotechnology Holdings, Inc. - Common Stock has 14M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.